Insider transaction
Patrick R. O’Neil, who serves as Executive Vice President, Chief Legal Officer and General Counsel at Ionis Pharmaceuticals, sold 6,179 shares of the company on January 30, 2026, for an aggregate value of approximately $516,153. According to the filing, the shares were disposed of at prices between $83.48 and $83.67 per share.
RSU vesting and post-transaction holdings
The firm's Form 4 filing with the Securities and Exchange Commission also records that O’Neil acquired 11,991 shares on January 29, 2026, with a reported value of $0 stemming from the vesting of performance-based restricted stock units. After the sale and the vesting event, O’Neil is listed as directly owning 71,983 shares of Ionis Pharmaceuticals.
Company developments noted in the filing
The filing accompanies a summary of recent corporate developments. The European Commission has approved Dawnzera for the prevention of hereditary angioedema attacks in patients aged 12 years and older, following results from Phase 3 clinical trials. In collaboration with GSK, an investigational hepatitis B drug developed with Ionis achieved statistically significant cure rates in Phase 3 testing for chronic hepatitis B, according to the reported updates.
Analyst coverage reflected the company’s progress: RBC Capital lifted its price target for Ionis Pharmaceuticals to $95 while keeping an Outperform rating, citing the firm’s evolution into a fully integrated commercial entity. TD Cowen reiterated a Buy rating with a $99 price target, highlighting expected growth driven by multiple products including Tryngolza and Dawnzera. Additionally, the FDA granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease following positive study results.
Context and implications
The filing presents the insider transaction in parallel with a string of regulatory and clinical updates and recent analyst actions. The document shows O’Neil’s sale, the vesting of performance-based awards, and the insider’s remaining stake, while separately listing milestones and analyst perspectives that the company has disclosed.
Key points
- Ionis CLO Patrick R. O’Neil sold 6,179 shares on January 30, 2026, for about $516,153 at prices between $83.48 and $83.67.
- O’Neil had 11,991 performance-based restricted stock units vest on January 29, 2026, recorded at a value of $0, and now directly holds 71,983 shares.
- Ionis reported multiple recent developments: EC approval of Dawnzera for hereditary angioedema in patients 12 and older, positive Phase 3 hepatitis B results from a GSK-partnered drug, analyst price-target increases from RBC Capital and TD Cowen, and FDA Breakthrough Therapy designation for zilganersen.
Risks and uncertainties
- Company performance as reflected in analyst price targets depends on the commercial and clinical progress of products named in the filing - developments cited include approvals and Phase 3 results.
- Clinical and regulatory outcomes are central to the updates reported; future study results and regulatory decisions will be material to product trajectories referenced in the filing.
The information above is drawn from the company's filing and the developments reported alongside it. The filing records the insider sale, RSU vesting, and post-transaction ownership, while the company updates summarize recent regulatory, clinical and analyst activity.